Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

Open access
Ku, Zhiqiang, Xie, Xuping, Hinton, Paul R., Liu, Xinli, Ye, Xiaohua, Muruato, Antonio E., Ng, Dean C., Biswas, Sujit, Zou, Jing, Liu, Yang, Pandya, Deepal, Menachery, Vineet D., Rahman, Sachi, Cao, Yu-An, Deng, Hui, Xiong, Wei, Carlin, Kevin B., Liu, Junquan, Su, Hang, Haanes, Elizabeth J., Keyt, Bruce A., Zhang, Ningyan, Carroll, Stephen F., Shi, Pei-Yong, An, Zhiqiang · 2021 · Nature

Abstract

Resistance represents a major challenge for antibody-based therapy for COVID-191–4. Here we engineered an immunoglobulin M (IgM) neutralizing antibody (IgM-14) to overcome the resistance encountered by immunoglobulin G (IgG)-based therapeutics. IgM-14 is over 230-fold more potent than its parental IgG-14 in neutralizing SARS-CoV-2. IgM-14 potently neutralizes the resistant virus raised by its corresponding IgG-14, three variants of concern—B.1.1.7 (Alpha, which first emerged in the UK), P.1 (Gamma, which first emerged in Brazil) and B.1.351 (Beta, which first emerged in South Africa)—and 21 other receptor-binding domain mutants, many of which are resistant to the IgG antibodies that have been authorized for emergency use. Although engineering IgG into IgM enhances antibody potency in general, selection of an optimal epitope is critical for identifying the most effective IgM that can overcome resistance. In mice, a single intranasal dose of IgM-14 at 0.044 mg per kg body weight confers prophylactic efficacy and a single dose at 0.4 mg per kg confers therapeutic efficacy against SARS-CoV-2. IgM-14, but not IgG-14, also confers potent therapeutic protection against the P.1 and B.1.351 variants. IgM-14 exhibits desirable pharmacokinetics and safety profiles when administered intranasally in rodents. Our results show that intranasal administration of an engineered IgM can improve efficacy, reduce resistance and simplify the prophylactic and therapeutic treatment of COVID-19. An engineered IgM antibody administered intranasally in mice shows high prophylactic efficacy and therapeutic efficacy against SARS-CoV-2, and is also effective against multiple variants of concern that are resistant to IgG-based therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03673-2

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 176

Metadata

Authors
Ku, Z., Xie, X., Hinton, P. R., Liu, X., Ye, X., Muruato, A. E., Ng, D. C., Biswas, S., Zou, J., Liu, Y., Pandya, D., Menachery, V. D., Rahman, S., Cao, Y.-A., Deng, H., Xiong, W., Carlin, K. B., Liu, J., Su, H., Haanes, E. J., Keyt, B. A., Zhang, N., Carroll, S. F., Shi, P.-Y., & An, Z.
Venue
Nature
Published
2021-06-03
Volume
595
Issue
7869
Pages
718-723
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3164232357
Cited by
176
References
10
FWCI
10.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. https://app.cochat.ai/papers/10.1038/s41586-021-03673-2
The paper
Ku, Z., Xie, X., Hinton, P. R., Liu, X., Ye, X., Muruato, A. E., Ng, D. C., Biswas, S., Zou, J., Liu, Y., Pandya, D., Menachery, V. D., Rahman, S., Cao, Y.-A., Deng, H., Xiong, W., Carlin, K. B., Liu, J., Su, H., . . . An, Z. (2021). Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. https://doi.org/10.1038/s41586-021-03673-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.